GERON CORPORATION (NASDAQ:GERN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 9, 2017, Geron Corporation (the Company) held its 2017
Annual Meeting of Stockholders (the Annual Meeting) at the
Companys offices located at 149 Commonwealth Drive, Menlo Park,
CA 94025, and via conference call, to notice duly given. Only
stockholders of record as of the close of business on March 13,
2017 (the Record Date) were entitled to vote at the Annual
Meeting. As of the Record Date for the Annual Meeting,
159,158,636 shares of common stock of the Company were
outstanding and entitled to vote at the Annual Meeting, of which
125,152,324 shares of common stock of the Company were
represented, in person or by proxy, constituting a quorum. The
final results of the stockholder vote on each proposal brought
before the Annual Meeting were as follows:
(a) Proposal 1. Each of the three (3) named
nominees to hold office as Class III members of the Board of
Directors (the Board) to serve for a three-year term expiring at
the Companys 2020 annual meeting of stockholders was elected
based upon the following votes:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes | |||
| Karin Eastham | 44,724,968 | 6,697,362 | 73,729,994 | |||
| V. Bryan Lawlis, Ph.D. | 44,262,388 | 7,159,942 | 73,729,994 | |||
| Susan M. Molineaux, Ph.D. | 44,039,917 | 7,382,413 | 73,729,994 |
(b) Proposal 2. The non-binding advisory vote on
named executive officer compensation was approved based upon the
following votes:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| 40,529,615 | 10,283,291 | 609,424 | 73,729,994 |
(c) Proposal 3. The non-binding advisory vote on
the frequency of holding future non-binding advisory votes on
executive compensation received the following votes:
| 1 Year | 2 Years | 3 Years | Abstentions | Broker Non-Votes | ||||
| 46,680,474 | 668,328 | 3,584,454 | 489,074 | 73,729,994 |
In light of the vote of the stockholders on this proposal and
consistent with the Boards recommendation, the Company will
continue to include a non-binding stockholder advisory vote to
approve the compensation of its named executive officers in its
proxy materials every year. The Company will hold such annual
advisory votes until the next required vote on the frequency of
stockholder votes on named executive officer compensation. The
Company is required to hold votes on the frequency of holding
future non-binding advisory votes on executive compensation every
six calendar years.
(d) Proposal 4. The selection of Ernst Young LLP
as the Companys independent registered public accounting firm for
the fiscal year ending December 31, 2017 was ratified based upon
the following votes:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
| 121,022,761 | 3,307,623 | 821,940 |
1
About GERON CORPORATION (NASDAQ:GERN)
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. GERON CORPORATION (NASDAQ:GERN) Recent Trading Information
GERON CORPORATION (NASDAQ:GERN) closed its last trading session up +0.09 at 2.68 with 1,921,051 shares trading hands.